Literature DB >> 16432268

Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers.

John S Markowitz1, C Lindsay DeVane, Robert J Malcolm, Holly A Gefroh, Jun-Sheng Wang, Hao-Jie Zhu, Jennifer L Donovan.   

Abstract

Olanzapine (OLZ) is a second-generation antipsychotic agent available in 2 solid oral dosage forms, a standard oral tablet (SOT) and an orally disintegrating tablet (ODT). This study assessed the absorption of each by different routes of administration. Secondarily, the influence of P-glycoprotein (P-gp) genotype was assessed. It was hypothesized that more rapid absorption of the OLZ ODT would occur when administered sublingually versus standard oral administration. A randomized, 3-way crossover study assessed the 5-mg OLZ formulations in healthy volunteers (n = 10). Blood was collected (0-8 hours) to assess OLZ pharmacokinetics using liquid chromatography/mass spectrometry. Both routes of ODT administration resulted in more measurable early concentrations relative to SOT. However, there were no statistically significant differences observed between any of the OLZ exposures for observed pharmacokinetic parameters (C(max), T(max), AUC(0-8h)). The homozygous TT genotype for P-gp resulted in an increased AUC of OLZ for SOT administration but not for either condition where sublingual absorption could occur.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432268     DOI: 10.1177/0091270005283839

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

1.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

2.  Long-term treatment with atypical antipsychotics and risk of weight gain.

Authors:  Emmanuel Stip; Karyne Anselmo; Marcel Wolfe; Christiane Lessard; Pierre Landry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

4.  Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.

Authors:  Sarah Baltzley; Atiquzzaman Mohammad; Ahmad H Malkawi; Abeer M Al-Ghananeem
Journal:  AAPS PharmSciTech       Date:  2014-08-21       Impact factor: 3.246

5.  Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.

Authors:  Anyue Yin; Dewei Shang; Yuguan Wen; Liang Li; Tianyan Zhou; Wei Lu
Journal:  Eur J Clin Pharmacol       Date:  2016-04-27       Impact factor: 2.953

Review 6.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

7.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

Review 8.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

9.  Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.

Authors:  William Montgomery; Tamas Treuer; Jamie Karagianis; Haya Ascher-Svanum; Gavan Harrison
Journal:  Patient Prefer Adherence       Date:  2012-02-01       Impact factor: 2.711

Review 10.  The Benefits of Olanzapine in Palliating Symptoms.

Authors:  Mellar P Davis; Gareth J Sanger
Journal:  Curr Treat Options Oncol       Date:  2020-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.